热门资讯> 正文
Jaguar Health公布第四季度业绩
2026-04-08 12:41
- Jaguar Health press release (JAGX): Q4 Revenue of $3.2M (-8.6% Y/Y).
- Net loss attributable to common shareholders increased by approximately $15.1 million, from $38.5 million in the year ended December 31, 2024 to $53.6 million in 2025.
- Mytesi prescription volume decreased approximately 3.7% in the year 2025 over 2024, by approximately 5.8% in the fourth quarter of 2025 over the third quarter of 2025, and by approximately 12.2% in the fourth quarter of 2025 over the fourth quarter of 2024.
- For the fourth quarter of 2025, the Company recognized license fees of $42,500 from a securities purchase agreement with a European partner.
- Revenues for the non-prescription Neonorm products were minimal for the fourth quarters of 2025 and 2024.
More on Jaguar Health
- Seeking Alpha’s Quant Rating on Jaguar Health
- Historical earnings data for Jaguar Health
- Financial information for Jaguar Health
推荐文章
SpaceX在发现多项问题后推迟“星舰”第12次试飞
华盛早报 | 沃什今晚11点宣誓就职美联储主席！雷军称未来两年内存或持续涨价；Q1恒指季检结果今晚公布
美股机会日报 | 伊朗称高浓缩铀不得运往国外；特朗普再出手！美国政府20亿美元布局量子计算；SpaceX正式递表冲刺纳斯达克
一图看懂 | 连续两季盈利！蔚来Q1经营利润0.66亿元，交付量超8万辆；毛利率创近四年新高
SpaceX更多IPO细节披露：去年亏损49亿美元，马斯克掌握85%投票权，股票分阶段解禁
英伟达上调股息，市场投资者担忧其未来增长前景
伊朗战事引发市场集体焦虑！美财长发话：收益率与通胀上升是 “暂时的”
SpaceX IPO招股书首度曝光：星链年赚113亿美元，航天业务亏损，估值剑指1.8万亿美元！
风险及免责提示：以上内容仅代表作者的个人立场和观点，不代表华盛的任何立场，华盛亦无法证实上述内容的真实性、准确性和原创性。投资者在做出任何投资决定前，应结合自身情况，考虑投资产品的风险。必要时，请咨询专业投资顾问的意见。华盛不提供任何投资建议，对此亦不做任何承诺和保证。
